TY - JOUR
T1 - Left frontal lobe hypoperfusion and depressive symptoms in Alzheimer's disease patients taking cholinesterase inhibitors
AU - Oshima, Etsuko
AU - Terada, Seishi
AU - Sato, Shuhei
AU - Ikeda, Chikako
AU - Oda, Kouji
AU - Inoue, Shinichiro
AU - Kawada, Kiyohiro
AU - Yokota, Osamu
AU - Uchitomi, Yosuke
N1 - Funding Information:
We sincerely thank Ms. Horiuchi, Ms. Imai, and Ms. Yabe for their skillful assistance. This work was supported by grants from the Japanese Ministry of Education, Culture, Sports, Science and Technology ( 21591517 ), and the Zikei Institute of Psychiatry .
Publisher Copyright:
© 2014 Elsevier Ireland Ltd. All rights reserved.
PY - 2014
Y1 - 2014
N2 - Depressive symptoms are common in patients with Alzheimer's disease (AD) and increase the caregiver burden. Many studies have reported dorsolateral prefrontal hypometabolism or hypoperfusion in AD patients with depressive symptoms, most of whom did not take acetylcholinesterase inhibitors (AChEI). It is not clear, however, whether a similar condition is present in patients taking AChEI medication. Fifty-seven consecutive AD patients taking AChEI were recruited at a memory clinic. Objective depressive symptoms were evaluated using the depression domain of the Neuropsychiatric Inventory (NPI-dep). All patients underwent brain single photon emission computed tomography (SPECT) with 99mTc-ethylcysteinate dimer, and the SPECT images were analyzed using the Statistical Parametric Mapping 8 program. No significant differences between groups with positive and negative NPI-dep scores were found with respect to age, sex, years of education, and cognitive function. Compared with patients with negative NPI-dep scores, patients with NPI-dep scores ≥1 showed significant hypoperfusion in the left middle frontal region. Our results indicate that the dorsolateral prefrontal area is significantly involved in the pathogenesis of depressive symptoms in AD patients being treated with AChEI. The area on the left side especially may be closely related to the depressive symptoms evaluated using the NPI.
AB - Depressive symptoms are common in patients with Alzheimer's disease (AD) and increase the caregiver burden. Many studies have reported dorsolateral prefrontal hypometabolism or hypoperfusion in AD patients with depressive symptoms, most of whom did not take acetylcholinesterase inhibitors (AChEI). It is not clear, however, whether a similar condition is present in patients taking AChEI medication. Fifty-seven consecutive AD patients taking AChEI were recruited at a memory clinic. Objective depressive symptoms were evaluated using the depression domain of the Neuropsychiatric Inventory (NPI-dep). All patients underwent brain single photon emission computed tomography (SPECT) with 99mTc-ethylcysteinate dimer, and the SPECT images were analyzed using the Statistical Parametric Mapping 8 program. No significant differences between groups with positive and negative NPI-dep scores were found with respect to age, sex, years of education, and cognitive function. Compared with patients with negative NPI-dep scores, patients with NPI-dep scores ≥1 showed significant hypoperfusion in the left middle frontal region. Our results indicate that the dorsolateral prefrontal area is significantly involved in the pathogenesis of depressive symptoms in AD patients being treated with AChEI. The area on the left side especially may be closely related to the depressive symptoms evaluated using the NPI.
KW - Acetylcholine esterase inhibitor (AChEI)
KW - Alzheimer's disease
KW - Depression
KW - Neuropsychiatric inventory (NPI)
KW - Regional cerebral blood flow (rCBF)
UR - http://www.scopus.com/inward/record.url?scp=84935513097&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84935513097&partnerID=8YFLogxK
U2 - 10.1016/j.pscychresns.2014.10.008
DO - 10.1016/j.pscychresns.2014.10.008
M3 - Article
C2 - 25453992
AN - SCOPUS:84935513097
SN - 0925-4927
VL - 224
SP - 319
EP - 323
JO - Psychiatry Research - Neuroimaging
JF - Psychiatry Research - Neuroimaging
IS - 3
ER -
